Abstract
71st Scientific sessions of American Diabetes Association 2011 - Post-Conference Review and Analysis
Summary
GlobalData, the industry analysis specialist, has released its new conference alerts, “71st Scientific sessions of American Diabetes Association 2011 - Post-Conference Review and Analysis”. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.
71st Scientific sessions of American Diabetes Association 2011 was held in San Diego, between June 24-28, 2011, organized by the American Diabetes Association. The five day conference include a demonstration of improvements in both treatment options for diabetes and understanding of the mechanisms behind the disease. This report, entitled “71st Scientific sessions of American Diabetes Association 2011 - Post-Conference Review and Analysis”, aims to cover the scientific presentations and articles released during the course of the conference.
Scope
The report provides complete coverage of conference. Its scope includes -
• Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
• Review of pre- and post-conference KOL/analyst comments.
• Market revenue data for 2010 and forecast forward to 2017 for a specific disease area (if the conference being covered is focused on a specific disease area).
• Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.
Reasons To Buy
The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
• Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
• Explore M&A opportunities by identifying key products and market players.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the market opportunities.
• Make more informed business decisions from the insightful and in-depth analysis of the market and the factors influencing the same.
Table of Contents
1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 71st Scientific Sessions of American Diabetes Association 2011 - Post-Conference Highlights
2.1 Effect of Multiple Doses of TAK-875 on the Pharmacokinetics of a Single Dose of Repaglinide
2.2 Ultra-Long-Acting Insulin Degludec - Two Different Formulations (U100 and U200) Are Bioequivalent and Show Similar Pharmacodynamics.
2.3 Safety Profile of Saxagliptin (SAXA) in Combination with 2 Other Agents - Data from Dual-Therapy Trials in Patients Receiving Rescue Treatment
2.4 Glucose-Lowering Effects of an Oral Glucokinase (GK) Activator, MK-0941, in Patients with Type 2 Diabetes (T2DM) Inadequately Controlled by Metformin
2.5 Systematic Review on Berberine in the Treatment of Type 2 Diabetes
2.6 LAPS-Exendin-4 Analog, a Novel Long-Acting GLP-1R Agonist for Weekly or Monthly Dosing in T2 DM Patients
2.7 Combination Therapy with Anti-IL1β Antibodies and Islet Auto-Antigen GAD65 Reverts Recent-Onsent Diabetes in the RIP-GP Mouse Model
2.8 The Randomized, Double-Blind, Placebo-Controlled Study for Diacerein Treatment on Microalbuminuria in Patients with Type 2 Diabetes Mellitus.
2.9 Pharmacokinetic/Pharmacodynamic Modeling of TAK-875, a Novel GPR40 Agonist, in Japanese Patients with Type 2 Diabetics
2.10 The Novel DPP-4 Inhibitor Linagliptin Is Associated with a Very Low Risk of Hypoglycemia - Results from a Large Phase III Program
2.11 Effect of the Once-Daily GLP-1R Agonist Lixisenatide on Gastric Emptying and Prandial Carbohydrate Utilization in Animal Models - A Comparison with Liraglutide.
2.12 Efficacy and Safety of Linagliptin in Type 2 Diabetes Patients at High Risk of Renal Complications - Results from a Large Phase 3 Program
2.13 Pioglitazone Compared to Glibenclamide on Lipid Profile and Inflammation Markers in Type 2 Diabetic Patients during Oral Fat Load
2.14 Long Term Effects of Insulin Therapy with or without Addition of Oral Antidiabetic Drugs in Patients with Diabetes Mellitus Type 2
2.15 Additional Glucose-Lowering Effects of the Oral GK Activator, MK-0941, in Patients with T2DM on Basal Insulin
2.16 Alogliptin Decreases Liver Fat Content in Patients with IGT or Type 2 DM - Comparing Alogliptin and Voglibose
2.17 Comparison of Incretin-Based Therapies - Liraglutide Offers Greater Improvements in A1c Than Sitagliptin or Exenatide across Baseline A1c Categories
2.18 Effects of Canagliflozin on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Metformin and Glyburide
2.19 Safety and Efficacy of Long Acting Glucagon like Peptide-1 Agonists Compared to Other Incretin-Based Therapies in Type 2 Diabetes - A Systematic Review and Meta-Analysis
2.20 Acarbose Attenuates Postprandial Hypotension in Older Adults with Type 2 Diabetes Mellitus
2.21 Effects of Dapagliflozin on Patient Reported Treatment Satisfaction in Patients with Type 2 Diabetes Mellitus - Results from Two Double-Blind Trials
2.22 Discovery of Bi-Functional Peptides Balanced in Glucagon Antagonism & GLP-1 Agonism. A Search for the Molecular Basis in the Inversion of Activity at Homologous Receptors
2.23 Characteristics of 833 Patients Newly Treated with GLP-1 Analogs or DPP-IV Inhibitors in 38 Diabetes Specialized Medical Practices in Germany
2.24 Initial Treatment with Sitagliptin as Monotherapy or Combination Therapy Improves Markers of β-Cell Function in Patients with Type 2 Diabetes
2.25 Teplizumab Treatment Induces Migration of Human T Regulatory Lymphocytes to the Small Intestine In Vivo
2.26 Stimulating Beta Cell Replication and Improving Islet Graft Function by AR231453, a GPR119 Agonist
2.27 An Experimental Study on Treatment of Diabetic Rats through Transplantation of Allogeneic Bone Marrow Mesenchymal Stem Cells
2.28 Successful Switch from Insulin Therapy to a Metformin/Saxagliptin Combination Therapy in Patients with Type 2 Diabetes. Interim Results from the SAXAswitch Study
2.29 Pharmacokinetics and Pharmacodynamics of BI 10773, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, and Linagliptin, a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, Following Co-Administration in Healthy Volunteers
2.30 Initial Therapy with the Fixed-Dose Combination (FDC) of Sitagliptin and Metformin (JANUMET™) in Patients with Type 2 Diabetes Mellitus (T2DM) Provided Superior Glycemic Control vs. Metformin Alone, Based on the AACE/ACE Diabetes Algorithm
2.31 A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of the Novel GPR40 Agonist TAK-875 in Subjects with T2DM
3 Abbreviations
3.1 Disclaimer
List of Tables
1.1 List of Tables
Table 1: Safety Profile of Saxagliptin (SAXA) in Combination with Metformin and Pioglitazone
Table 2: Effects of Canagliflozin on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Metformin and Glyburide
Table 3: Results from Initial Treatment with Sitagliptin as Monotherapy and Combination Therapy
Table 4: Results from the Treatment of Diabetic Rats through Transplantation of Allogeneic Bone Marrow Mesenchymal Stem Cells
Table 5 : Levels of Glycemic Control on Treatment with an FDC of Sitagliptin/Metformin Vs Metformin alone
List of Figures
1.2 List of Figures
Figure 1: Efficacy and Safety of Linagliptin
Figure 2: Percentage A1c Changes from Baseline in Liraglutide, Exenatide, Sitagliptin.
Figure 3: Hemodynamic Response to Standardized Meal
Figure 4: Change from Baseline in HbA1c (%)
